

Sir Ian DIXON, C.B.E.
Sir Andrew LARGE.

His Royal Highness The PRINCE OF WALES, acting on behalf of Her Majesty The QUEEN by authority of Letters Patent under the Great Seal of The Realm dated 19th February 1996 conferred the Honour of Knighthood upon the undermentioned at Buckingham Palace on Friday, 31st May 1996:

Sir Peter BONFIELD, C.B.E.

(Her Majesty's approval of these Knighthoods was signified on 30th December 1995)

The Honourable Sir Cyril FOUNTAIN.

(Her Majesty's approval of this Knighthood was signified on 23rd January 1996)

Sir Harold PLATT.

(Her Majesty's approval of this Knighthood was signified on 17th June 1995)

Sir Timothy WARD.

(Her Majesty's approval of this Knighthood was signified on 31st December 1993)

Her Royal Highness The PRINCESS ROYAL, acting on behalf of Her Majesty The QUEEN by authority of Letters Patent under the Great Seal of the Realm dated 17th May 1996 conferred the Honour of Knighthood upon the undermentioned at The Palace of Holyroodhouse on Wednesday, 22nd May 1996:

Professor Sir David CARTER.
Professor Sir Graeme DAVIES.

(Her Majesty's approval of these Knighthoods was signified on 30th December 1995)

(1 SI)

HOME OFFICE

Queen Anne's Gate,
London SW1H 9AT

The QUEEN has been pleased to approve the appointment of Mrs. Phyllida Katherine Stewart-Roberts O.B.E., J.P., D.L., to be Vice Lord-Lieutenant for the county of East Sussex to act for Her Majesty's Lord-Lieutenant during his absence from the county, sickness or other inability to act.

(4 SI)

Miss Dempsey

DEPARTMENT OF HEALTH

Medicines Division, Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Telephone 0171-273 0422, or 0425

Product Licences Granted

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
00001/0217	CIBA-GEIGY PLC	Bradosol Flavoured Lozenges	Benzalkonium Chloride -500 mg	The lozenges are intended for the relief of sore throats. General Sales List	6th June 1996
00001/0222	CIBA-GEIGY PLC	Aredia Dry Powder 30 mg	Pamidronate Disodium Anhydrous 30 000 mg	Treatment of conditions associated with increased osteoclast activity. Tumour-induced hypercalcaemia, Osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma, Paget's disease of bone Prescription only medicine	12th June 1996
00012/0296	May & Baker Limited, t/a May & Baker, Rhone-Poulenc Rorer, Rorer Pharmaceuticals, Pharmuka, Theraplax, APS & Berk Pharmaceuticals	Calcitare	Porcine Calcitonin BP 160-00 iu	For the short term treatment in Paget's disease of bone and Hypercalcaemia. Prescription only medicine	3rd June 1996
00012/0297	May & Baker Limited, t/a May & Baker, Rhone-Poulenc Rorer, Rorer Pharmaceuticals, Pharmuka, Theraplax, APS & Berk Pharmaceuticals	Calsynar 400 iu/2 ml Vial	Salcatonin BP 400 00 iu	For the short term treatment of: Paget's disease of bone, Advancing Osteolytic Hypercalcaemia of Malignancy, Pain associated with advanced metastatic bone cancer- the use of Calsynar has been reported to be beneficial in the relief of pain in some patients with advanced metastatic bone cancer, and Postmenopausal osteoporosis- studies based on total body calcium determinations have indicated that Calsynar may be effective in the prevention of progressive loss of bone mass in the treatment of postmenopausal osteoporosis. Prescription only medicine	3rd June 1996
00012/0298	May & Baker Limited, t/a May & Baker, Rhone-Poulenc Rorer, Rorer Pharmaceuticals, Pharmuka, Theraplax, APS & Berk Pharmaceuticals	Calsynar Ampoules 100 iu	High Purity Salcatonin B.P. Specification Ref. R180/3	In the treatment of Paget's disease and various hypercalcaemias. Prescription only medicine	3rd June 1996
00031/0346	Roche Products Limited	Konakion MM Paediatric 2 mg/0.2 ml	Vitamin K1 2 000 mg	For prophylaxis and treatment of haemorrhagic disease of the newborn. Prescription only medicine	20th June 1996
00049/0037	Colgate-Palmolive (UK) Limited	Colgate Total Fresh Stripe Toothpaste	Sodium Fluoride 320 ww, Sodium Fluoride 320 ww, Triclosan 300 ww, Triclosan 300 ww	To reduce dental caries. To improve gingival health by significantly reducing the formation of plaque and calculus and significantly reducing existing levels of gingival bleeding and inflammation. General sales list	19th June 1996